Reply

Dear Editor,
Our recently published article in the Brazilian Archives of Cardiologia 1 aimed to evaluate the implementation of vaccination against influenza (INF) and Pneumococcus virus (pneumonia) in a specific subgroup of patients with heart failure (HF), due to consensus recommendation of the NorthAmerican, European and Brazilian guidelines on HF. The increased susceptibility to respiratory infections in patients with heart failure is attributed to pulmonary congestion.
Martins et al 1 recommend measures for increasing influenza and pneumococcal immunization based on the reduced rates detected in patients with heart failure in the city of Teresopolis. We understand that, in spite of the benefit of this strategy at the population level to prevent infections and complications, we must evaluate mass vaccination and immunization extended to special groups such as immunologically susceptible individuals and those with comorbidities Even vaccines made from inactivated agents may trigger important and unpredictable reactions, such as, for instance, Guillain-Barre syndrome.
We recently reported a case series of symptomatic pericardial effusion with increased incidence in patients who received influenza vaccine. The patients, mostly elderly and individuals with compensated diseases, showed viral symptoms, increased incidence in the peri-immunization period and resolution of the clinical draw with anti-inflammatory drug use 3 . Post-vaccination myopericarditis has been reported and may be underdiagnosed and sub-notified 4, 5 .
And what about the popular culture? Why so many people are afraid about influenza vaccination? Wouldn't it be due to the fear about the frequent, often undisclosed and nonbenign reactions?
A definitive and consistent position depends on further and unbiased phase-4 studies, designed for special groups subject to vaccination, in spite of any economic impact produced by eventual results.
Respiratory infections stand out among the three most frequent causes of decompensation in patients with HF. Each episode of decompensation adversely affects the life expectancy of patients with HF. Epidemiological evidence points to a major benefit of vaccination in the elderly population and there is no consistent evidence against vaccination in susceptible subgroups, such as those with chronic diseases, especially in HF.
No health intervention is completely risk-free. The decision for the inclusion of a specific vaccine in clinical practice requires a cost-effectiveness analysis from the clinical and epidemiological points of view. The adverse events In spite of the possibility of pericarditis as AEFI, it normally has a benign course, as opposed to respiratory infections in patients with HF.
In our clinical practice in the HF Clinics of Centro Universitário Serra dos Órgãos (Teresópolis-RJ) and Universidade Federal Fluminense (Niterói-RJ), we have recommended the routine vaccination of the 350 patients treated there, with no record of occurrences. Hence, we have observed a decrease in the number of hospitalizations, obviously within the context of many other implemented actions. We reaffirm that, in light of current evidence, especially the amount of more than 150 million doses given since the program was initiated in Brazil, vaccination against PNM and INF has shown to be safe and effective and thus it is recommended for the subgroup of patients with HF, as shown in the III Brazilian Guidelines on Chronic HF.
Sincerely,
Wolney de Andrade Martins
By the authors
